Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings (TTM) are $15.42 B. an increase over its 2022 earnings that were of $9.78 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 | $15.42 B | 57.64% |
2022 | $9.78 B | 5.35% |
2021 | $9.29 B | 12.47% |
2020 | $8.26 B | 13.07% |
2019 | $7.30 B | -3.35% |
2018 | $7.55 B | 1.79% |
2017 | $7.42 B | 4.52% |
2016 | $7.10 B | 9.42% |
2015 | $6.49 B | 8.24% |
2014 | $5.99 B | 3.45% |
2013 | $5.79 B | 19.02% |
2012 | $4.87 B | 15.21% |
2011 | $4.22 B | 17.71% |
2010 | $3.59 B | 24.78% |
2009 | $2.87 B | 10.62% |
2008 | $2.60 B | 55.97% |
2007 | $1.66 B | 7.07% |
2006 | $1.55 B | 18.18% |
2005 | $1.31 B | 11.33% |
2004 | $1.18 B | |
2002 | $0.76 B | -14.39% |
2001 | $0.89 B |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | -78.83% | ๐บ๐ธ USA |
Eli Lilly LLY | $6.55 B | -57.52% | ๐บ๐ธ USA |
Sanofi SNY | $8.39 B | -45.59% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | $8.44 B | -45.30% | ๐บ๐ธ USA |